Events

Videos

Podcasts

Articles

Hematologic Oncology

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Treatment with single-agent ibrutinib dramatically increased PFS by nearly 80% and significantly extended OS by 57% compared with ofatumumab in patients with relapsed or refractory CLL.

Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial

Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the implications of ibrutinib's approval for patients with mantle cell lymphoma (MCL).

Dr. Younes on the Implications of Ibrutinib's Approval for MCL

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment.  This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Mantle Cell Lymphoma | Specialty

Ibrutinib Triples PFS, Doubles OS in Phase III CLL Trial

Dr. Younes on the Implications of Ibrutinib's Approval for MCL